Table 2 Endoscopy data and comparison between bleeding and non-rebleeding groups
Variables | No-rebleeding n = 1035 (88.5%) | Rebleeding n = 135 (11.5%) | P-value |
|---|---|---|---|
Duodenal ulcer | 475 (45.8%) | 51 (3.7%) | 0.075 |
Gastric ulcer | 251 (24.2%) | 33 (24.4%) | 0.233 |
Esophageal varices | 150 (14.4%) | 27 (20%) | 0.093 |
Gastric carcinoma | 61 (5.8%) | 12 (8.8) | 0.176 |
Mallory–Weiss | 41 (3.96%) | 6 (4.4%) | 0.788 |
Gastroduodenal anastomotic ulcer | 22 (2.1%) | 1 (0.7%) | 0.276 |
Dieulafoy disease | 12 (1.1%) | 0 | 0.209 |
Esophageal carcinoma | 9 (0.8%) | 3 (2.2%) | 0.142 |
Gastric stromal tumor | 8 (0.7%) | 0 | 0.305 |
Duodenal carcinoma | 6 (0.5%) | 2 (1.4%) | 0.232 |
Endoscopic hemostasis | |||
Mechanical therapy | 427 (41.2%) | 52 (38.5%) | 0.543 |
Combination therapy | 231 (22.3%) | 39 (28.8%) | 0.088 |
Injection therapy | 229 (22.1%) | 20 (14.8%) | 0.051 |
Electric coagulation | 148 (14.2%) | 24 (17.7%) | 0.283 |